Not Yet Recruiting
Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants - CV018-023
Mis à jour:
11 mai, 2020
|
ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Site(s)
Not Yet Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations; no significant findings in medical history. - Body mass index of 18.0 kg/m2 to 30.0 kg/m2, inclusive, at screening - Males must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Women of childbearing potential (WOCBP) - Known previous exposure to BMS-986235 - History of any significant drug allergy Other protocol-defined inclusion/exclusion criteria apply
Nous vous recommandons vivement de contacter BMS pour signaler les effets secondaires (événements indésirables)
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici
Signaler des plaintes concernant des effets indésirables (effets indésirables) ou des produits: Informations médicales